|
|
|
| home > > winter 2021 > overcoming the challenge of accurate supplier labelling |
|
|
 PUBLICATIONS |
Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time.
Sign up now!
Already registered? Please sign in.
Alternatively, please use our pay-per-view service. |
|
|
 |
Industry Events |
 |
DIA Europe 2021
15-19 March 2021, VIRTUAL CONFERENCE
DIA Europe is the must-attend event for all life science professionals
working in drug development, from discovery to marketed use. It
encourages open collaboration by bringing together representatives from
the entire spectrum of the life science landscape and facilitating
crucial discussions across several topic tracks: Clinical Development,
Regulatory Strategy, Pharmacovigilance, Value and Access, Health Policy,
and many more.
More info >> |
|
 |
News and Press Releases |
 |
Cobra Biologics completes production of Master Cell Banks for CombiGene’s epilepsy gene therapy drug candidate
Lund, Sweden and Keele, UK, 18 August 2020. Cobra Biologics (Cobra), part of the Cognate BioServices family, an international CDMO manufacturer of biological materials and pharmaceuticals, and CombiGene AB (publ) (CombiGene), the leading gene therapy company in the Nordic region, today announced that Cobra has successfully produced master cell banks for the three plasmids used as starting material for CombiGene’s gene therapy CG01. Critical to assuring ‘life time’ supply of therapeutic, this represents a further milestone in the future commercial manufacture of a drug candidate designed for the treatment of drug-resistant focal epilepsy.
More info >> |
|
|
